Clinical Trial: Xeomin vs Botox for Treatment of Overactive Bladder Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Overactive Bladder Syndrome
Study Type: INTERVENTIONAL
Official Title: IncobotulinumtoxinA (Xeomin®) vs OnabotulimuntoxinA (Botox®) for Treatment of Overactive Bladder Syndrome: Randomized Non-Inferiority Trial
Brief Summary:
Purpose: Multiple formulations and brands of botulinum toxin exist on the market today.Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder.IncobotulinumtoxinA (XEOMIN®) is a similar formulation of botulinum toxin A that has similar dosing and safety profile at onabotulinumtoxinA.OnabotulinumtoxinA is the most expensive formulation on the market.Compare the efficacy of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals) to onabotulinumtoxinA (Botox®, Allergan) for…
Read more